Sarclisa

[Chinese name]: Isatuximab

[Trade name]: Isatuximab

[Chemical name]: Sarclisa

[Pharmaceutical manufacturer]: Sanofi

[Specification]: 500mg/25 ml

[All names]: Isatuximab, Sarclisa, Isatuximab

Indications

Relapsed or refractory multiple myeloma

< br>

Usage and Dosage

When used concomitantly with pomalidomide and dexamethasone, the usual adult dose of isatuximab (genetically recombinant) is 10 mg/kg as an intravenous infusion. 28 days as a cycle, the first cycle is performed 4 times at 1-week intervals (1, 8, 15, 22 days), 2 times at 2-week intervals (1, 15 days), and then 2 cycles.

Mechanism of action

Isatuximab binds to human CD38 and induces tumor growth by inducing antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC) activities and apoptosis. It is believed that it can be suppressed.

Anti-tumor effect Isatuximab showed an inhibitory effect on tumor growth in severe combined immunodeficiency mice subcutaneously transplanted with the human multiple myeloma-derived MOLP-8 cell line.

Packaging

Intravenous drip

100mg 5mLx1 bottle

500mg 25mLx1 bottle

Storage/validity period

Stored at 2-8°C

Validity period 36 months